Biol Reprod Lalor Postdoctoral Fellowships -- Application Deadline January 15, 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.
Agricola
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.
Biology of Reproduction 67, 776-781 (2002)
© 2002 Society for the Study of Reproduction, Inc.


Regular Article

Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-4 on Human Granulosa Cell Steroidogenesis1

Rebecca J. Wright2,a, Jeffrey M.P. Hollyb, Ray Galeac, Mark Brincatc, and Helen D. Masona

a Department of Obstetrics and Gynaecology and Department of Physiology, St. George's Hospital Medical School, Tooting, London SW17 0RE, United Kingdom b Department of Surgery, Bristol Royal Infirmary, Bristol University, Bristol BS2 8HW, United Kingdom c Department of Obstetrics and Gynaecology, University of Malta Medical School, Msida, Malta, United Kingdom


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The ovarian insulin-like growth factor (IGF)/IGF binding protein (IGFBP) system operates to permit maximal stimulation of steroidogenesis in the dominant follicle. In atretic follicles, the predominant IGFBPs are IGFBP-2 and IGFBP-4, which appear to be selectively cleaved in healthy follicles. We have recently demonstrated potent inhibition by IGFBP-4 of both theca and granulosa cell steroid production. The degree to which the inhibition occurred suggested that it was greater than might be expected by sequestration of IGF alone. Our study was designed to test this idea. Granulosa cells were harvested from follicles dissected intact from patients undergoing total abdominal hysterectomy and bilateral salpingoophorectomy. Granulosa cells were incubated with or without gonadotropins and IGFBP-4 in the presence or absence of either the IGF type I receptor blocker {alpha}IR3 or excess IGFBP-3 to remove the effects of endogenous IGF action. Steroid accumulation in the medium was assessed. IGFBP-4 continued to exert potent inhibitory effects when the action of endogenous IGF was removed from the system, demonstrating that its actions are independent of IGF binding. There was no effect on cell metabolism, and the effects on steroidogenesis were reversible after IGFBP-4 removal from the culture medium. No similar effects were seen with IGFBP-2. These reasults are the first evidence of IGF-independent IGFBP-4 actions and the first evidence of IGF-independent actions of any IGFBPs in the ovary.

granulosa cells, growth factors, insulin-like growth factor receptor, ovary, steroid hormones


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The ovarian insulin-like growth factor (IGF) system has come under considerable scrutiny in recent years, and it is now clear that there are changes in the components of the system with follicle development. In humans, these changes include induction of IGF-II production [1], the increased responsiveness of granulosa cells to IGFs [2], and the production of IGF binding protein (IGFBP) proteases, presumably to increase IGF bioavailability [3, 4]. All of these changes are directed toward increasing the steroidogenic capacity of the healthy follicle. We and others have shown clear differences between healthy and atretic follicles in the profile of IGFBPs in follicular fluid and in theca-conditioned medium [57]. A consistent finding is that IGFBP-2 and -4 are proteolysed in follicular fluid from healthy follicles but are intact in follicles judged to be atretic. Likewise, only follicular fluid from healthy follicles was able to proteolyze radiolabeled recombinant IGFBP-4 [7]. Increased fragmentation of IGFBP-4 was also seen in medium conditioned by theca from healthy compared with atretic follicles. Interestingly, the fragment sizes found in medium from our cultures of theca tissue were different from those present in follicular fluid, suggesting the possibility of compartmentalization of protease activity within the ovary [7].

In an earlier study, we demonstrated partial inhibition of FSH-stimulated steroidogenesis by incubation of granulosa cells with IGFBP-1 or -3, which we suggested was due to the sequestration of IGF-II in these cultures [8]. Recently, we reported an inhibitory effect of IGFBP-4 on both granulosa and theca steroidogenesis that was more potent than might be expected by sequestration of IGF alone [9] and was more potent than that previously seen with IGFBP-3 or -1. We hypothesized that the effects of IGFBP-4 in these experiments are independent of its ability to bind IGF. The series of experiments reported here were designed to test this hypothesis


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Patients

Ovaries were obtained from women undergoing oophorectomy for nonovarian gynecological disease. All patients were cycling regularly except one who reported polymenorrhea and one with oligomenorrhea. Cycle stage was random, and none of the patients had received medication for stimulation or suppression of ovarian function for at least 3 mo prior to surgery. Patient details are given in Table 1. Approval for this study was granted by the local ethics committes and by the Ethics Committee of the Faculty of Medicine and Surgery, Medical School, Malta. Informed consent was obtained from each patient prior to surgery. Morphological category was assigned according to previously published criteria [10]. Most of the ovaries collected were ovulatory and polycystic.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Clinical details of patients from whom ovarian tissue was collected. The size and range of follicles from which cells were pooled is also given. In three cases, some details were not known (NK)

Cell Cultures

Follicles were microscopically dissected intact from the ovaries, the diameter was measured, and follicular fluid was aspirated. Granulosa cells were harvested and cultured as previously described [11]. Experiments were carried out on pooled cells from a single patient or on cells from individual follicles where stated. In one experiment, cells were pooled from two patients. Details of the size of follicles from which cells were pooled is shown in Table 1. Approximately 5 x 104 viable cells/well were incubated in a 200-µl volume of serum-free Medium 199 (Gibco BRL, Paisley, U.K.) with the addition of antibiotics (penicillin and streptomycin; Gibco BRL) and 200 mM L-glutamine. Incubations were carried out in the presence of 10-7 M testosterone (Sigma Chemical Co., Poole, U.K.) as an aromatase substrate. One experiment was carried out using cells collected at the time of oocyte aspiration from patients undergoing ovarian stimulation for in vitro fertilization. Following removal of the oocyte, aspirates were pooled and granulosa cells were separated from blood cells and other debris using the method of Abeyasekara et al. [12].

Experimental Protocol

Experiments were performed on cells from six patients, two of whom had normal ovaries and four of whom had ovulatory polycystic ovaries. Cells were incubated in medium alone or in medium containing 5 ng/ml highly purified human pituitary LH or FSH (Endocrine Services, Bidford-on-Avon, U.K.) with or without IGFBP-4 (Austral Biologicals, San Ramon, CA) at 5 or 50 ng/ml, doses that previously caused maximum inhibition of steroid production [9]. All cultures were performed with the addition of 5 x 10-7 M testosterone as an aromatase substrate.

Although the majority of these experiments were conducted with cells from small follicles in which the levels of endogenous IGF would be expected to be very low or absent, to negate the contribution of any endogenous IGF to the steroid production, experiments were carried out in the presence of the specific IGF-I receptor monoclonal antibody {alpha}IR-3 (Oncogene Science, Cambridge, U.K.) [13], which is purified on a protein-G affinity column. The concentration of antibody used (100 ng/ml) had previously been determined to completely inhibit the stimulatory effects of addition of 10 ng/ml IGF-I in granulosa cells [2]. A control to demonstrate this inhibition was added to each experiment.

To further demonstrate IGF-independent effects, a second series of experiments was performed in which IGFBP-4 was added in the presence of 50 ng/ml IGFBP-3, a concentration calculated to bind any endogenous IGF-II, previously found to be <10 ng/ml [4]. In addition to IGFBP-4, IGFBP-2 is also selectively cleaved in follicular fluid from healthy follicles, and in a further experiment the effects of IGFBP-2, -3, and -4 were compared in the same pool of cells. To investigate the degree of fragmentation of the IGFBPs under these experimental conditions, medium was subsequently subjected to immunoblot for IGFBP-3 and -4, and the percentage of fragmentation was calculated after densitometric analysis of bands representing intact and fragmented IGFBP.

All treatments were added simultaneously. Cultures were incubated for 48 h, the medium was collected, and estradiol (E2) and progesterone accumulations were measured with an in-house RIA, as previously described [14, 15]. This nonextraction method was specifically designed for use with culture medium, using antibodies supplied by Guildhay (Guildford, Surrey, U.K.).

We also performed two experiments to determine the permanency of the IGFBP-4 inhibitory effects and to see whether IGFBP-4 also affected cell viability or metabolism. To investigate the reversibility of IGFBP-4 effects, one set of cells was incubated with FSH with and without IGFBP-4 for 24 h, after which the medium was replaced by medium containing LH alone for a further 24 h. To test for possible effects of IGFBP-4 on cell viability, medium was removed and cells were exposed to a colorimetric assay in which the cells are incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma). The assay gives a qualitative assessment of mitochondrial dehydrogenase enzyme activity, which converts MTT to dark blue formazon. The resultant color change measured by optical density is proportional to the metabolic activity and number of cells [16].

Each test substance was added to three to six wells. Results are expressed as the mean and standard error. Differences between treatments were assessed with a Mann-Whitney U-test, with significance assumed at P < 0.05.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
IGF Independence of IGFBP-4 Effects

Significant inhibition of basal steroid production by IGFBP-4 was seen in three of five experiments performed in various pools of cells from three different patients (Fig. 1, a–c, first two bars). The degree of inhibition of both progesterone and E2 was variable. In the same experiments, gonadotropin stimulated steroid production, which was inhibited by IGFBP-4 in all experiments. Figure 1a shows progesterone results from granulosa cells from a single follicle 12 mm in diameter. Similar results were obtained for E2 in the same wells. Results for E2 from granulosa cells pooled from small follicles from the same ovary are shown in Figure 1b and those for cells from small follicles from a second ovary are shown in Figure 1c. The results for progesterone in these experiments were similar to those for E2.



View larger version (45K):
[in this window]
[in a new window]
 
FIG. 1. Granulosa cell steroidogenesis. All results are the mean and SEM of triplicate wells. The size of follicles from which cells were pooled in each case is shown in the inset. a) Left to right: Basal progesterone (P) (C, control), inhibition by IGFBP-4 (not significant), stimulation by FSH (P < 0.05), inhibition of FSH action by IGFBP-4 (P < 0.05), stimulation by IGF-I, no significant effect of {alpha}IR-3 alone, inhibition of IGF response to basal levels by {alpha}IR-3, no effect of {alpha}IR-3 on FSH-stimulated P, IGFBP-4 inhibition of FSH-stimulated P even in the presence of {alpha}IR-3 (a vs. b, P < 0.05). Similar results were obtained for E2 in the same wells. b) Cells from small follicles from the same ovary. No effect of IGFBP-4 on basal E2, significant inhibition of FSH-stimulated E2 by IGFBP-4 (P < 0.01), no effect of {alpha}IR-3 alone, inhibition of IGF effects, no significant effects of {alpha}IR-3 on FSH-stimulated E2, significant inhibition of FSH-stimulted E2 by IGFBP-4 in presence of {alpha}IR-3 (a vs. b, P < 0.05). c) Granulosa cells from a second ovary. IGFBP-4 inhibited LH-stimulated E2 production to basal levels. Incubation with levels of {alpha}IR-3 sufficient to inhibit the effect of added IGF-I did not significantly affect the inhibitory action of IGFBP-4 (a vs. b, P < 0.05)

Addition of {alpha}IR-3 in these experiments had a slight agonistic or no effect on basal and gonadotropin-stimulated E2 and progesterone production, demonstrating that endogenous IGF was either absent or at a very low level. Likewise, addition of {alpha}IR-3 in the presence of FSH had little effect on the level of steroid, indicating that neither FSH nor LH stimulated IGF-II production in these experiments and that endogenous IGF did not contribute significantly to the steroid response. The effectiveness of the antibody in this system was demonstrated by the fact that addition of 100 ng/ml of {alpha}IR-3 completely inhibited steroid production stimulated by addition of IGF-I.

Incubation of cells in the presence of {alpha}IR-3 did not affect the inhibitory action of IGFBP-4 on FSH-stimulated steroidogenesis (Fig. 1, a–c, last bars). Similar results were obtained for E2 and progesterone in cells pooled from small follicles from a third pair of ovaries (data not shown).

The results of addition of IGFBP-4 in the presence of IGFBP-3 on FSH-stimulated E2 and progesterone production are shown in Figure 2, a and b. IGFBP-4 inhibited the stimulatory effects of FSH in each case. Coincubation with IGFBP-3 had no significant effect on FSH-stimulated steroid production in cells from these small follicles, again suggesting that the levels of endogenous IGF were low. IGFBP-4 continued to cause inhibition of E2 and progesterone even in the presence of IGFBP-3, which had previously been shown to negate the effects of IGF-I [8]. Similar results were obtained in luteinized cells collected as a by-product of oocyte aspiration in patients undergoing egg collection for in vitro fertilization (Fig. 2c).



View larger version (53K):
[in this window]
[in a new window]
 
FIG. 2. Effect of addition of saturating concentrations of IGFBP-3 on action of IGFBP-4. a) FSH (5 ng/ml) stimulated E2 levels above those seen with testosterone alone (C); IGFBP-4 inhibited FSH-stimulated E2 production to basal levels; addition of IGFBP-3 to FSH had no effect on E2 production; addition of IGFBP-4 in the presence of IGFBP-3 inhibited E2 levels to baseline (a vs. b and c vs. d, not significant). b) Results for progesterone were similar. Results are mean (SEM) of four wells. c) Inhibition of steroidogenesis by luteinized cells by IGFBP-4 (a vs. b, P < 0.02) or IGFBP-4 plus 50 ng/ml IGFBP-3 (a vs. c, P < 0.005). Note inhibitory effects of IGFBP-3 in these cells, which are known to produce IGFs

Recovery of Steroidogenic Capacity FollowingIGFBP-4 Treatment

In this experiment, IGFBP-4 inhibited LH-stimulated progesterone production during the first 24 h of incubation (Fig. 3). After the medium was removed and the cells were restimulated with LH, there was complete recovery of progesterone production to levels observed in cells that had not been exposed to IGFBP-4, and there was partial recovery of E2 production.



View larger version (52K):
[in this window]
[in a new window]
 
FIG. 3. Recovery of steroidogenic capacity by granulosa cells treated with IGFBP-4. Bars represent mean (SEM) of six wells. First 24 h: addition of IGFBP-4 inhibited FSH-stimulated E2 (hatched bars, left scale) and progesterone (P; open bars, right scale) production. Medium was then replaced with medium containing testosterone alone (C + t) or LH (5 ng/ml) for a futher 24 h. Second 24 h: addition of LH resulted in recovery of P and E2 levels to those seen in cells not previously exposed to IGFBP-4 (a vs. c and b vs. d, not significant)

Comparative Effects of IGFBP-2, -3, and -4

Comparison of the effects of IGFBP-2, -3, and -4 revealed that only IGFBP-4 significantly inhibited granulosa cell E2 production (Fig. 4). In cells from this pool of follicles, IGFBP-2 had no effect and IGFBP-3 caused a slight but not significant inhibition of steroidogenesis. Western immunoblotting of media containing exogenous IGFBP-2 and -3 revealed that the vast majority of the binding protein remained in the intact form (data not shown). This finding was particularly apparent for IGFBP-2, where <1% was fragmented.



View larger version (53K):
[in this window]
[in a new window]
 
FIG. 4. Comparison of the effects of equal doses of IGFBP-2, -3, or -4 on FSH-stimulated E2 production. Data are the mean (SEM) of six wells. Note lack of effect of IGFBP-2, slight inhibition by IGFBP-3, and inhibition to basal levels with IGFBP-4 (a vs. b and a vs. c, not significant; a vs. d, P < 0.01)

MTT Results

There was no significant difference between any of the treatments in the optical density of medium in the wells in the MTT assay.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We have demonstrated that the potent inhibitory effects of IGFBP-4 on steroidogenesis by granulosa cells occur even in the presence of levels of {alpha}IR-3 known to block the effects of endogenous IGF. The {alpha}IR-3 antibody is highly specific for and binds with high affinity to the IGF-I receptor. Because IGF-II is known to exert its effects via this receptor [2] and IGF-I is not made by these cells [17], all effects of IGF should be negated in these experiments. The lack of effects of {alpha}IR-3 and IGFBP-3 in our experiments however demonstrates that the levels of endogenous IGF were very low in these cultures. This finding suggests that IGFBP-4 is acting on these cells in a manner independent of its ability to sequester IGF. This is the first demonstration of IGF-independent effects of IGFBP-4 and the first demonstration that IGFBPs may have IGF-independent effects in the ovary.

There was significant inhibition of basal steroid production in approximately half of our experiments, whereas IGFBP-4 consistently inhibited gonadotropin-stimulated steroid production. There were no consistent differences in the composition of follicle pools that could account for the inconsistency in basal inhibition.

IGF-independent effects of IGFBPs have been demonstrated in a variety of cells types, but to date these effects have been shown only for those IGFBPs known to interact with cell surface or extracellular matrix binding sites. For example, IGFBP-1 stimulates the migration of smooth muscle cells by a mechanism involving binding to the integrin receptor [18]. Nuclear localization of IGFBP-3 and -5 has been recently reported, presenting an intriguing possibility for the mechanism of action of IGFBPs in some cell types [19, 20]. At present, we have no data to suggest a mechanism by which IGFBP-4 may be exerting its effects.

The majority of women undergoing total abdominal hysterectomy and bilateral salpingoophorectmy have ovulatory polycystic ovaries (personal observation). Although cells from these ovaries are poor responders to gonadotropin [10] and are therefore not ideal for experimental purposes, the supply of tissue is not such that all studies can be performed with normal ovaries. We considered the use of polycystic tissue for these studies valid because all of the pools of cells responded to gonadotropin and because we were not investigating the differential effects of IGFBP-4 in normal versuis polycystic ovaries, only on unluteinized granulosa cells in general.

The inhibitory effects of IGFBP-4 were confined to this binding protein alone; there was no or limited inhibition of E2 and progesterone production by IGFBP-3 or IGFBP-2 in these cells. IGF-I is not produced by human granulosa cells, and according to previous work the IGF-II mRNA is not detectable until the follicle reaches 11 mm in size, i.e., following selection [1]. There are data, however, to suggest that IGF-II production may be stimulated in response to FSH and other factors in these cells [21, 22], which may explain the limited effect of IGFBP-3 on these cells. In our experiments, {alpha}IR-3 had little or no effect even in the presence of gonadotropin, indicating that the levels of endogenous IGF were low throughout. Proteolysis of IGFBP-2 in follicular fluid from healthy follicles has been reported consistently and appears to be a prerequisite for folliculogenesis; however, our data indicate that this proteolysis does not appear to be due to the antigonadotropic effects of IGFBP-2. We have been unable to detect IGFBP-3 in granulosa cell-conditioned medium, and although IGFBP-2 was present it was always entirely in the intact form [7]. In the experiments reported here, the vast majority of the binding protein remained in the intact form at the end of the culture period, demonstrating that the differences in inhibitory activity of these IGFBPs cannot be due to differences in fragmentation in the medium. Further work is required to elucidate the role of IGFBP-2 in the ovary.

The degree to which IGFBP-4 was antigonadotropic in these cells emphasizes the physiological reason for its removal from healthy follicles. There was complete recovery of progesterone secretion and partial recovery of E2 secretion following removal of IGFBP-4, showing that the effects of the binding protein were reversible. IGFBP-4 does not cause cell death or toxicity, as further supported by the lack of an effect on metabolism in these cells as indicated by the results of the MMT assay. Removal of IGFBP-4 in the ovary is achieved both by suppression of mRNA production and by proteolytic cleavage. Although we and others have demonstrated IGFBP-4 proteolytic activity in follicular fluid of all sizes of healthy follicles, we have only seen activity in one sample of granulosa cell-conditioned medium, which was from a 25-mm preovulatory follicle [23] Proteolysis of IGFBP-4 in granulosa cells was induced by FSH in rat granulosa cells and by FSH and IGF-I in luteinized human granulosa cells [24, 25], but addition of IGFs in the present study had no effect on protease production by granulosa cells from small follicles.

We are currently investigating the possible presence of an inhibitor of this activity. Others have suggested that in fibroblasts at least the specific IGFBP-4 protease is pregnancy-associated plasma protein A (PAPP-A) [26]. The presence of PAPP-A has been demonstrated in follicular fluid, and levels were higher in estrogen-dominant follicles [27]. This protein and its possible role as an IGFBP-4 protease will no doubt be the focus of considerable interest in the near future.

There have been several reports of high levels of IGFBP-4 in follicular fluid from polycystic ovaries. Falling levels of IGFBP-4 were found in a spontaneous preovulatory follicle from a woman with polycystic ovaries [28]. Given the potency of the inhibitory effects of IGFBP-4 on follicular cells, it is possible to envision a role for IGFBP-4 in the apparent inability of these cells to respond to FSH in vivo. Removal of the cells from the follicular endocrine milieu by culturing them would then allow steroidogenesis to continue. Alternatively, increasing the intrafollicular levels of FSH by treatment may induce IGFBP-4 proteolysis and allow steroidogenesis to proceed. It is impossible to determine whether the follicles have stopped growing because IGFBP-4 levels are higher or vice versa.

IGFBP-4 has a potent IGF-independent antigonadotropic effect on human granulosa cells. No similar effects were seen for IGFBP-2 or -3. These results indicate a physiological reason for the preferential proteolytic cleavage of IGFBP-4 in healthy follicles. The mode of action of IGFBP-4 and the role of IGFBP-2 in granulosa cells are currently under investigation.


    FOOTNOTES
 
First decision: 3 December 2001.

1 This work was supported by The Wellcome Trust. Back

2 Correspondence. FAX: 44 208 725 2993; rwright{at}sghms.ac.uk Back

Accepted: April 4, 2002.

Received: November 16, 2001.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Voutillainen R, Franks S, Mason HD, Martikainen H. Expression of insulin-like growth factor (IGF) binding protein and IGF receptor mRNAs in normal and polycystic ovaries. J Clin Endocrinol Metab 1996 81:1003-1008[Abstract]
  2. Willis DS, Mason HD, Watson H, Franks S. Developmentally regulated responses of human granulosa cells to insulin-like growth factors (IGFs): IGF-I and IGF-II action mediated via the type-I IGF receptor. J Clin Endocrinol Metab 1998 83:1256-1260[Abstract/Free Full Text]
  3. Giudice L, van-Dessel HJ, Cataldo NA, Chandresekher YA, Yap OW, Fauser BC. Circulating and ovarian IGF-binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome. Prog Growth Factor Res 1995 6:397-408[CrossRef][Medline]
  4. Mason HD, Davies SC, Franks S, Holly JMP. Insulin-like growth factor I and II (IGF I and II), IGF binding proteins and IGFBP proteases are produced by normal and polycystic human ovaries. J Clin Endocrinol Metab 1996 81:206-213
  5. San Roman GA, Magoffin DA. Insulin-like growth factor binding proteins in healthy and atretic follicles during natural menstrual cycles. J Clin Endocrinol Metab 1993 76:625-632[Abstract]
  6. Cataldo NC, Woodruff TK, Giudice LC. Regulation of insulin-like growth factor binding protein production by human luteinizing granulosa cells cultured in defined medium. J Clin Endocrinol Metab 1993 76:207-215[Abstract]
  7. Cwyfan-Hughes S, Mason HD, Franks S, Holly JMP. Modulation of the insulin-like growth factor binding proteins by follicle size in the human ovary. J Endocrinol 1997 154:35-43[Abstract/Free Full Text]
  8. Mason HD, Willis D, Holly JMP, Cwyfan-Hughes SC, Seppala M, Franks S. Inhibitory effects of insulin-like growth factor-binding proteins on steroidogenesis by human granulosa cells in culture. Mol Cell Endocrinol 1992 89:R1-R4[CrossRef][Medline]
  9. Mason HD, Cwyfan-Hughes S, Franks S, Holly JMP. Potent inhibition of human ovarian steroidogenesis by insulin-like growth factor binding protein-4. J Clin Endocrinol Metab 1998 83:284-287[Abstract/Free Full Text]
  10. Mason HD, Willis DS, Beard RW, Winston RML, Margara R, Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotrophins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994 79:1355-1360[Abstract]
  11. Mason HD, Davies S, Franks S, Holly JMP. Insulin-like growth factor-I (IGF-I) inhibits IGFBP-1 whilst stimulating estradiol production by granulosa cells from normal and polycystic human ovaries. J Clin Endocrinol Metab 1993 76:1275-1279[Abstract]
  12. Abeyasekara DR, Jones PM, Persaud SJ, Michael AE, Flint APS. Prostaglandin F2{alpha} activates protein kinase c in human ovarian cells. Mol Cell Endocrinol 1993 91:51-57[CrossRef][Medline]
  13. Kull FC, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin C. J Clin Chem 1998 258:6561-6566
  14. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994 79:1158-1165[Abstract]
  15. Willis DS, Mason HD, Gilling-Smith C, Franks S. Modulation by insulin of follicle stimulating hormone and luteinising hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996 81:302-309[Abstract]
  16. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983 65:55-63[CrossRef][Medline]
  17. Geisthovel F, Moretti-Rojas IM, Asch RH, Rojas FJ. Expression of insulin-like growth factor II (IGF-II) messenger ribonucleic acid (mRNA) but not IGF-I mRNA in human preovulatory granulosa cells. Hum Reprod 1989 4:899-902[Abstract/Free Full Text]
  18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995 16:3-34[CrossRef][Medline]
  19. Li WL, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA. Nuclear transport of insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 1997 138:1763-1766[Abstract/Free Full Text]
  20. Jaques G, Noll K, Wegmann B, Witten S, Kogen E, Radulescu RT, Havemann K. Nuclear localization of insulin-like growth factor binding protein-3 in a lung cancer cell line. Endocrinology 1997 138::1767-1770[Abstract/Free Full Text]
  21. Voutilainen R, Miller WL. Coordinate trophic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain cleavage enzyme, P450scc, in human steroidogenic tissues. Proc Natl Acad Sci U S A 1987 84:1590-1594[Abstract/Free Full Text]
  22. Ramasharma K, Li CH. Human pituitary and placental hormones control human insulin-like growth factor II secretion in human granulosa cells. Proc Natl Acad Sci U S A 1987 84:2643-2647[Abstract/Free Full Text]
  23. Wright R, Perks C, Holly JMP, Mason HD. Production and proteolysis of IGFBP-4 in the human ovary. In: Program of the Insulin-Like Growth Factor Binding Protein Workshop; 2000; Terrigal, Australia (abstract)
  24. Choi D, Putowski LT, Fielder PJ, Rosenreld RG, Rohan RM, Adashi EY. Characterisation and hormonal regulation of granulosa cell-derived insulin-like growth factor binding protein-4. J Soc Gynaecol Invest 1996 3:145-151
  25. Iwashita M, Kudo Y, Takeda Y. Effect of follicle stimulating hormone and insulin-like growth factor-I on proteolysis of IGFBP-4 in human granulosa cells. Mol Hum Reprod 1998 4:401-406[Abstract/Free Full Text]
  26. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates III JR, Conover CA. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy associated plama protein-A. Proc Natl Acad Sci U S A 1999 96:3149-3153[Abstract/Free Full Text]
  27. Conover CA, Oxvig C, Overgaard MT, Christiansen M, Giudice LC. Evidence that the insulin-like growth factor binding protein-4 protease in human ovarian follicular fluid is pregnancy associated plasma protein-A. J Clin Endocrinol Metab 1999 84:4742-4745[Abstract/Free Full Text]
  28. Magoffin DA, San Roman GA, Muderspach LI. Insulin-like growth factor binding proteins in a natural pre-ovulatory follicle from a woman with polycystic ovary syndrome. Hum Reprod 1995 10:2248-2252[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J ANIM SCIHome page
A. J. Roberts, M. J. Al-Hassan, P. M. Fricke, and S. E. Echternkamp
Large variation in steroid concentrations and insulin-like growth factor binding proteins exists among individual small antral follicles collected from within cows at random stages of the estrous cycle
J Anim Sci, October 1, 2006; 84(10): 2714 - 2724.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
I. Ben-Ami, S. Freimann, L. Armon, A. Dantes, R. Ron-El, and A. Amsterdam
Novel function of ovarian growth factors: combined studies by DNA microarray, biochemical and physiological approaches
Mol. Hum. Reprod., July 1, 2006; 12(7): 413 - 419.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
M Munoz-Gutierrez, P A Findlay, C L Adam, G Wax, B K Campbell, N R Kendall, M Khalid, M Forsberg, and R J Scaramuzzi
The ovarian expression of mRNAs for aromatase, IGF-I receptor, IGF-binding protein-2, -4 and -5, leptin and leptin receptor in cycling ewes after three days of leptin infusion
Reproduction, December 1, 2005; 130(6): 869 - 881.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
E D Watson, S-E Bae, R Thomassen, S R M Thomson, K Woad, and D G Armstrong
Insulin-like growth factors-I and -II and insulin-like growth factor-binding protein-2 in dominant equine follicles during spring transition and the ovulatory season
Reproduction, September 1, 2004; 128(3): 321 - 329.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.
Agricola
Right arrow Articles by Wright, R. J.
Right arrow Articles by Mason, H. D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS